REG - Cambridge Cognition - Notice of AGM

Cambridge Cognition HoldingsAnnouncement

04/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250604:nRSD2940La&default-theme=true

RNS Number : 2940L  Cambridge Cognition Holdings PLC  04 June 2025

 

04 June 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Posting of Annual Report & Notice of AGM

 

Cambridge Cognition (AIM: COG), the brain health software group specialising
in digital products to advance clinical research and patient treatment,
confirms that the Annual Report and Accounts for the year ended 31 December
2024 ("2024 Annual Report and Accounts") and the Notice of the Annual General
Meeting ("AGM") have been published on the Company's website today. Hard
copies have been posted to those shareholders who requested them.

 

The AGM is to be held at 9:00 am on 27 June 2025 at the registered office of
the Company, Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU.

 

A copy of the 2024 Annual Report and Accounts and other documents are
available on the Company's website: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

Enquiries:

 

 Cambridge Cognition Holdings plc                    Tel: 012 2381 0700 

 Rob Baker, Joint Managing Director                  press@camcog.com (mailto:press@camcog.com)  

 and Chief Operating Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)    Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers          (Corporate Finance)

 Rupert Dearden                                      (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)              Tel: 020 3903 7715 

 David Poutney / Amber Philipps                       

 Hudson Sandler (Financial PR and IR)                Tel: 020 7796 4133 

 Dan de Belder / Hattie Dreyfus / Jackson Redley     cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

                            

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAPKNBDOBKDDAK